How BA/BE Studies Shape the Future of Generic Medicines Kumar Jeetendra | June 24, 2026 Generic medicines have become a cornerstone in healthcare as they allow healthcare systems to provide more affordable and accessible healthcare. Generic medicines must undergo significant scientific evaluations to ensure that they are as safe, high-quality, and therapeutically effective as the branded medications. Bioavailability (BA) and Bioequivalence (BE) studies are a key component in this scientific …
Pharma News Today: Healthcare Breakthroughs in 2026 Kumar Jeetendra | May 19, 2026 2026 marks a new chapter for the pharmaceutical and healthcare sectors. New technologies in AI, next generation biotech, and precision medicine, paired with new scientific discoveries, will attempt to meet the growing global demand for next generation healthcare. Innovations that include advanced biomanufacturing and smarter diagnostics will create therapies in a fraction of the time …
Innovations in Drug Discovery: Trends Redefining Pharma R&D Kumar Jeetendra | May 6, 2026 Can gene editing be used as a life-saving treatment? Could antiviral drugs that target human proteins be more effective than those than target the viruses themselves? The constant evolution of drug discovery is one of the most exciting aspects of modern medicine, and new research is leading to breakthroughs in precision medicine, cancer immunotherapy, neurodegenerative …
Alembic Pharmaceuticals Limited Gets USFDA Nod for Fingolimod 0.5 mg Kumar Jeetendra | May 1, 2026 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Fingolimod Capsules, 0.5 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis). Fingolimod is …
Inside Potassium Cyanide: Uses, Risks, and Scientific Insights Kumar Jeetendra | April 7, 2026 Potassium cyanide is infamous in the world for the extreme toxicity that gives it notoriety, combined with the usefulness it has in certain specific industrial and scientific uses. Its unique dual characteristics make it of great interest in analytical chemistry, industrial processing, toxicology, and the regulation of the science. What is Potassium Cyanide? Potassium Cyanide …
Ozempic & Semaglutide: Transforming Metabolic Treatment Kumar Jeetendra | March 30, 2026 For a number of years now, healthcare systems globally have centered their attention on improving metabolic health. The sharp rise of obesity and type 2 diabetes has highlighted the urgent require for treatments that are not only efficient but also sustainable. One of the most pioneering treatments has been Semaglutide or Ozempic. It has been …
Alembic Pharma Secures USFDA Tentative Approval for Bosutinib Kumar Jeetendra | February 9, 2026 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its supplemental Abbreviated New Drug Application (sANDA) Bosutinib Tablets, 400 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Bosulif Tablets, 400 mg, of PF Prism C.V. (PF Prism …
2025 in Review: A Defining Year for Pharma, Laboratory & Analytical Industry Kumar Jeetendra | January 6, 2026 By the end of 2025, the pharma, laboratory, and analytical sectors will have undergone an unprecedented overhaul. These industries overcame the pandemic bounce-back and are now completely transformed. Digital tools, regulatory oversight, analytical efficiency, and manufacturing breakthroughs have all advanced these markets.For scientists, manufacturers, solution providers, and leaders in these sectors, 2025 was about operational …
Alembic Pharma Gets USFDA Nod for Diltiazem HCl Tablets Kumar Jeetendra | November 17, 2025 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cardizem Tablets, 30 …
Alembic Gets USFDA Nod for Sumatriptan Injection Autoinjector Kumar Jeetendra | November 10, 2025 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Imitrex STATdose System, …
Common mistakes in pharma equipment disinfection and how to avoid them Kumar Jeetendra | November 9, 2025 A few months back, a leading Indian pharmaceutical company lost an entire production batch, bearing almost a ₹20 crore loss. The culprit was a tiny trace of residue on a mixing blade. No formulation error. No equipment failure. Just inadequate disinfection. These stories don’t make headlines, but they’re far more common than the industry likes …
Alembic Pharma Gets USFDA Nod for Ticagrelor 60 mg Tablets Kumar Jeetendra | November 1, 2025 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, 60 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Brilinta Tablets, 60 mg, of AstraZeneca Pharmaceuticals LP (AstraZeneca). Ticagrelor tablets are …
